Bio-Techne (TECH) stock
Health Care · Life Sciences Tools & Services
Bio-Techne (TECH) is a Life Sciences Tools & Services company in the Health Care sector, headquartered in Minneapolis, Minnesota. As of October 23, 2026, TECH closed at $72.55, a market capitalization of $11.38 billion, the 482nd largest company in the S&P 500. Over the last twelve months it generated $1.22 billion in revenue (+1% year over year) and $263.22 million in free cash flow. The stock trades at 62.5x trailing earnings and 31.4x forward earnings.
- 1-year total return: +10.4% (dividends reinvested)
- 5-year return: -10.1% a year
- 52-week range: $43.20 – $72.69
- Gross margin 66.2%, operating margin 27.9%
- Dividend yield: 0.44%
- FI Handbook report card: C across 10 metrics
- 56th largest of 60 Health Care stocks in the S&P 500
TECH price chart
1Y price change: +9.8% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| TECH | +0.0% | +23.9% | +10.4% | +5.1% | -10.1% | +11.4% | +19.4% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1989.
TECH key statistics
- Market cap
- $11.4B
- #482 in S&P 500
- P/E (TTM)
- 62.5x
- Forward P/E
- 31.4x
- EPS (TTM)
- $1.16
- Revenue (TTM)
- $1.2B
- +1%
- Free cash flow
- $263.2M
- Gross margin
- 66.2%
- Operating margin
- 27.9%
- Return on equity
- 9.0%
- Dividend yield
- 0.44%
- 52-week range
- $43.20 – $72.69
- Beta
- 1.29
- Price / sales
- 9.4x
- EV / EBITDA
- 34.1x
- Debt / equity
- 0.14x
- Employees
- 3,000
TECH report card
CTen fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth1.3%D
- Gross margin66.2%A
- Operating margin27.9%B
- FCF margin21.7%B
- Return on equity9.0%D
- Net debt / EBITDA0.1xB
- Forward P/E31.4xD
- PEG ratio2.1xD
- Shareholder yield0.8%D
- Share count change / yr-0.6%B
Bio-Techne financials
Revenue went from $563.0M in fiscal 2017 to $1.2B in fiscal 2026, growing 8.9% a year.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $563.0M | $643.0M | $714.0M | $738.7M | $931.0M | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B |
| Gross profit | $374.5M | $432.1M | $473.5M | $483.2M | $632.9M | $756.5M | $769.8M | $769.7M | $790.3M | $799.1M |
| Operating income | $120.6M | $136.2M | $146.7M | $157.4M | $237.3M | $296.6M | $298.9M | $206.7M | $102.3M | $251.9M |
| Net income | $76.1M | $126.2M | $96.1M | $229.3M | $140.4M | $272.1M | $285.3M | $168.1M | $73.4M | $181.9M |
| EPS (diluted) | $0.51 | $0.83 | $0.62 | $1.46 | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
| Free cash flow | $128.5M | $149.4M | $156.2M | $153.5M | $307.9M | $280.4M | $216.1M | $236.1M | $256.6M | $263.2M |
| Buybacks | — | $0 | $15.4M | $50.1M | $43.2M | $160.9M | $19.6M | $80.0M | $275.7M | $41.7M |
| Dividends paid | $47.3M | $48.0M | $48.4M | $48.9M | $49.6M | $50.2M | $50.3M | $50.4M | $50.4M | $49.9M |
| Diluted shares | 150.0M | 152.2M | 155.6M | 157.6M | 161.9M | 164.1M | 161.9M | 160.8M | 159.7M | 157.0M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into TECH?
A reverse DCF asks what growth the current price requires. With an enterprise value of $11.4B and $263.2M of trailing free cash flow, Bio-Techne needs to grow free cash flow about 30.6% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew -3.1% a year over the last five years.
P/E ratio history
Current 62.5x vs. median 42.0x (10th–90th percentile 22.5x–109.7x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
TECH dividend
- Dividend yield
- 0.44%
- Annual dividend
- $0.32
- Years of increases
- —
- 5-yr dividend growth
- 0.0%
- per year
- Payout ratio
- 28%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
TECH analyst price targets
10 analysts' average 12-month target is $70.50 (-3% vs. $72.55). Targets range from $50.00 to $73.00. 8% rate it a buy.
TECH earnings
Next report: November 9, 2026. Bio-Techne has beaten EPS estimates 1 quarters in a row. Last quarter's revenue was $321.2M (+1% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 12, 2026 | $0.52 | $0.52 | +0.1% |
| May 6, 2026 | $0.53 | $0.53 | -0.8% |
| Feb 4, 2026 | $0.43 | $0.46 | +5.8% |
| Nov 5, 2025 | $0.42 | $0.42 | -0.4% |
| Aug 6, 2025 | $0.50 | $0.53 | +5.8% |
| May 7, 2025 | $0.51 | $0.56 | +10.4% |
| Feb 5, 2025 | $0.39 | $0.42 | +7.8% |
| Oct 30, 2024 | $0.38 | $0.42 | +10.2% |
Stocks like TECH
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 TMO Thermo Fisher Scientific | -0.40% | +18% | $249.1B | 35.5x | Compare |
 DHR Danaher | +0.33% | +4% | $162.0B | 38.2x | Compare |
 A Agilent Technologies | -0.47% | +18% | $48.8B | 34.1x | Compare |
 IQV IQVIA | +0.37% | +27% | $46.0B | 34.7x | Compare |
 WAT Waters | -0.42% | +28% | $44.5B | 114.9x | Compare |
 ILMN Illumina | +0.01% | +170% | $40.7B | 50.3x | Compare |
 MTD Mettler-Toledo International, I | -0.85% | +16% | $33.5B | 37.6x | Compare |
 CRL Charles River Laboratories Inte | +1.68% | +81% | $16.6B | — | Compare |
TECH news
- 1 Unpopular Stock That Should Get More Attention and 2 We Question · Oct 9, 2026
- Bio-Techne opens GMP small molecule facility in Bristol, UK · Oct 9, 2026
- Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development · Oct 8, 2026
- 2 Cash-Producing Stocks Worth Investigating and 1 We Brush Off · Sep 28, 2026
- Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany · Sep 23, 2026
TECH stock FAQ
What is TECH's market cap?
Bio-Techne's market capitalization is $11.38 billion as of October 23, 2026, ranking 482nd in the S&P 500.
What is TECH's P/E ratio?
TECH trades at a trailing price-to-earnings ratio of 62.5x and a forward P/E of 31.4x. Its median P/E over the period we track is 42.0x.
Does TECH pay a dividend?
Yes. Bio-Techne pays $0.32 per share a year, a 0.44% yield. Dividends grew 0.0% a year over the last five years.
How much has TECH stock returned?
Including reinvested dividends, TECH returned +10.4% over one year, -10.1% a year over five years, +11.4% a year over ten years through October 23, 2026.
Is TECH stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Bio-Techne must grow free cash flow about 31% a year for the next decade. Its free cash flow fell 3% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the TECH price target?
10 analysts cover TECH with an average 12-month price target of $70.50, -3% from the current price. 8% of them rate it a buy.
When does TECH report earnings?
Bio-Techne is expected to report earnings on November 9, 2026. It has beaten EPS estimates 1 quarters in a row.
How many employees does Bio-Techne have?
Bio-Techne has about 3,000 full-time employees, or $405,013 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology